Elanco Animal Health (NYSE:ELAN) Hits New 1-Year High – What’s Next?

Elanco Animal Health Incorporated (NYSE:ELAN) shares reached a new 52-week high on Friday . The company traded as high as $19.36 and last traded at $19.37, with a volume of 988477 shares. The stock had previously closed at $18.92.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Leerink Partnrs upgraded Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. Leerink Partners raised Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective on the stock in a report on Thursday, July 17th. William Blair upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research report on Thursday, June 26th. UBS Group increased their price target on Elanco Animal Health from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, August 8th. Finally, Wall Street Zen upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.33.

Elanco Animal Health Trading Up 3.7%

The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The company has a market cap of $9.75 billion, a price-to-earnings ratio of 22.82, a P/E/G ratio of 3.64 and a beta of 1.62. The firm’s 50-day moving average price is $17.19 and its 200 day moving average price is $13.76.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.06. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the firm posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Allworth Financial LP increased its position in Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after purchasing an additional 2,090 shares in the last quarter. NBC Securities Inc. purchased a new stake in shares of Elanco Animal Health during the first quarter valued at $40,000. Parallel Advisors LLC lifted its holdings in Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock valued at $41,000 after acquiring an additional 1,852 shares during the period. Versant Capital Management Inc lifted its stake in shares of Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock valued at $46,000 after purchasing an additional 1,740 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its position in Elanco Animal Health by 184.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after acquiring an additional 2,414 shares during the period. 97.48% of the stock is owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.